Last updated: July 17, 2026

Application No. 17/509,970

Monoclonal Antibodies Against Pathological Alpha-Synuclein, and Methods Using Same

Non-Final OA

Filed

Oct 25, 2021

Priority

Aug 23, 2017 — provisional 62/549,197 +3 more

Examiner

BALLARD, KIMBERLY

Art Unit

1675

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

The Trustees of the University of Pennsylvania

OA Round

1 (Non-Final)

This examiner grants 54% of cases after interview

— +48.3% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 645 resolved cases, 2023–2026

Examiner Intelligence

BALLARD, KIMBERLY View full profile →

Grants 54% of resolved cases

Career Allowance Rate

348 granted / 645 resolved

-6.0% vs TC avg

Strong +48% interview lift

Without

With

+48.3%

Interview Lift

resolved cases with interview

Typical timeline

3y 3m

Avg Prosecution

32 currently pending

Career history

673

Total Applications

across all art units

Statute-Specific Performance

§101

3.0%

-37.0% vs TC avg

§103

36.9%

-3.1% vs TC avg

§102

18.8%

-21.2% vs TC avg

§112

13.4%

-26.6% vs TC avg

Black line = Tech Center average estimate • Based on career data from 645 resolved cases

Prosecution Timeline

Oct 25, 2021

Application Filed

Sep 10, 2025

Response after Non-Final Action

Apr 13, 2026

Non-Final Rejection mailed

Jul 10, 2026

Response Filed

Precedent Cases

Applications granted by this same examiner with similar technology

17/636,923

Patent 12649779

AMYLOID-BETA ANTIBODIES

4y 3m to grant Granted Jun 09, 2026

16/693,783

Patent 12618849

PEPTIDE ANALYZING METHOD

6y 5m to grant Granted May 05, 2026

16/936,457

Patent 12595295

DOSING REGIMES FOR TREATMENT OF SYNUCLEINOPATHIES

5y 8m to grant Granted Apr 07, 2026

17/105,858

Patent 12590130

BIPARTITE MOLECULES AND USES THEREOF IN TREATING DISEASES ASSOCIATED WITH ABNORMAL PROTEIN AGGREGATES

5y 4m to grant Granted Mar 31, 2026

17/665,057

Patent 12578348

BLOOD INDICATORS OF ALZHEIMER'S DISEASE

4y 1m to grant Granted Mar 17, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

54%

Grant Probability

99%

With Interview (+48.3%)

3y 3m (~0m remaining)

Median Time to Grant

Low

PTA Risk

Based on 645 resolved cases by this examiner. Grant probability derived from career allowance rate.